To screen ETFs by asset class, performance, yield and more, check out the
View as an RSS Feed
All Eyes Now Focusing On Acquisition Of Amarin
Amarin (AMRN -6.4%) trades lower on negative comments out of Summer Street this morning, saying that Vascepa might not be as key as previously thought. The firm notes that a member of AMRN's steering committee presented at a primary care conference last week, and said there was no reason to give Vascepa to patients with triglycerides <500 mg/dL until the outcome of current trials are completed, and, even if approval is granted early, sales are likely to disappoint.
"and, even if approval is granted early, sales are likely to disappoint." Although negative coverage, even they are not ruling anything out in terms early approval or on time approval. At this point, much to do about nothing.
May 28, 2013. 07:17 PM
Link to Comment
Xignite quote data
© 2015 Seeking Alpha